Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 433

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients

Open access
Petersen, Rebecca P., Campa, Michael J., Sperlazza, Justin, Conlon, Debbi, Joshi, Mary‐Beth, Harpole, David H., Patz, Edward F.·2006·Cancer

Abstract

BACKGROUND.: Early stage lung cancer has a variable prognosis, and there are currently no markers that predict which patients will recur. This study examined the relation between tumor‐regulatory T (Treg) cells and total tumor‐infiltrating T‐cell lymphocytes (TIL) to determine whether they correlated with recurrence. METHODS.: The authors reviewed all patients in our tissue databank from 1996 to 2001 and identified 64 consecutive pathologic stage I non‐small cell lung cancer (NSCLC) patients who had surgical resection and at least a 2.5 years disease‐free follow‐up or documented recurrence within 2 years. Immunohistochemical analyses were performed on paraffin‐embedded lung cancer tissue and the relation between Treg cells, TIL, and disease‐specific survival was determined. A risk index was devised deductively for various possible combinations of Treg cells and TIL. RESULTS.: Treg cells and TIL were detected in 33 of 64 (51%) and 53 of 64 (83%) patients, respectively. When data were analyzed by using a Treg/TIL Combination Risk Index, patients with high‐risk and intermediate‐risk indices had hazard ratios of 8.2 (P = .007) and 3.3 (P = .109), respectively. CONCLUSIONS.: Patients with stage I NSCLC who have a higher proportion of tumor Treg cells relative to TIL had a significantly higher risk of recurrence. These data may be useful, particularly if combined with a panel of tumor markers, to suggest at the time of diagnosis which patients with seemingly early‐stage NSCLC will relapse. Cancer 2006. © 2006 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.22282

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 433

Metadata

Authors
Petersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M., Harpole, D. H., & Patz, E. F.
Venue
Cancer
Publisher
Wiley
Published
2006-12-08
Volume
107
Issue
12
Pages
2866-2872
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2046609236
Cited by
433
References
29
FWCI
5.64
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients. https://app.cochat.ai/papers/10.1002/cncr.22282
The paper
Petersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M., Harpole, D. H., & Patz, E. F. (2006). Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. https://doi.org/10.1002/cncr.22282

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.